Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionVestmark Advisory Solutions, Inc.
Latest Disclosed Ownership6,957 shares
Latest Disclosed Value $ 3,106,579
Vestmark Advisory Solutions, Inc. reports 11.06% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Vestmark Advisory Solutions, Inc. filed a 13F-HR form disclosing ownership of 6,957 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $3,106,579 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 7,822 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -11.06% during the quarter. The current value of the position is $2,979,961 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,957 -865 -11.06 3,107 -12.41 0.0214
2026-02-06 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,822 -1,606 -17.03 3,546 -3.95 0.0479
2025-11-10 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,428 665 7.59 3,692 -5.36 0.0704
2025-08-06 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,763 -3,625 -29.26 3,901 -35.04 0.0563
2025-05-13 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,388 6,595 113.84 6,006 157.50 0.1546
2025-02-06 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,793 -346 -5.64 2,333 -18.32 0.0803
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,139 26 0.43 2,855 -0.35 0.1063
2024-08-12 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,113 4,610 306.72 2,865 356.21 0.1196
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,503 -2 -0.13 628 2.61 0.0271
2024-02-06 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,505 -164 -9.83 612 5.52 0.0311
2023-11-06 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,669 -15,332 -90.18 580 -90.30 0.0422
2023-08-07 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 17,001 -219 -1.27 5,983 10.27 0.2278
2023-05-09 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 17,220 -734 -4.09 5,426 4.65 0.2350
2023-01-20 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 17,954 -204 -1.12 5,185 -1.39 0.2526
2022-11-03 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18,158 -591 -3.15 5,257 -0.51 0.2930
2022-08-04 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18,749 -1,024 -5.18 5,284 2.40 0.3018
2022-04-27 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 19,773 -209 -1.05 5,160 17.59 0.2921
2022-01-31 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 19,982 -357 -1.76 4,388 18.95 0.2476
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 20,339 -400 -1.93 3,689 -11.79 0.2498
2021-08-09 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 20,739 1,197 6.13 4,182 -0.40 0.2976
2021-05-10 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 19,542 4,009 25.81 4,199 14.38 0.3725
2021-02-04 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 15,533 1,712 12.39 3,671 -2.39 0.4119
2020-10-19 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,821 2,128 18.20 3,761 10.78 0.5053
2020-08-13 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,693 817 7.51 3,395 31.18 0.5253
2020-05-06 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,876 -530 -4.65 2,588 3.64 0.5059
2020-02-14 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,406 -239 -2.05 2,497 26.56 0.5124
2019-11-05 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,645 -309 -2.58 1,973 -9.99 0.3199
2019-08-20 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,954 97 0.82 2,192 0.50 0.3751
2019-05-14 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,857 11,857 2,181 0.3889
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.